VivoSeq
Metabolic & Endocrine

Hypertriglyceridemia

55

Pipeline Programs↗

11

Active Trials↗

36

Companies Involved↗

Hypertriglyceridemia is a moderately active landscape with 55 programs across 36 companies. The most active players are Grace Therapeutics Inc., Fujian Shengdi Pharmaceutical Co., Ltd., Novartis. 11 therapies are approved with 18 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

19/100

Mech. Concentration

21/100

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Grace Therapeutics Inc.

2 programs

Phase 2F

Fujian Shengdi Pharmaceutical Co., Ltd.

2 programs

Phase 2Novartis logo

Novartis

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 289bio logo

89bio

1 program

Phase 2Z

Zhejiang Doer Biologics Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

54 of 61 classified programs — the dominant modality here.

11%ALL OTHERSRNA therapy47%Monoclonal antibody23%Protein / enzyme12%

Small molecule leads; the ring shows all 61 classified programs, each share of the total. Modality classified for 97% of 64 pipeline programs.

Analysis

Trial Status

61

clinical trials

Completed37 · 61%
Unknown status6 · 10%
Recruiting5 · 8%
Terminated5 · 8%
Active, not recruiting4 · 7%
Withdrawn1 · 2%
Other3 · 5%

Clinical Trials

Trial Activity

61 trials

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
Recruiting·OOrsoBio, Inc·Phase 2·NCT06564584·30 enrolled
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Recruiting·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 3·NCT06822790·869 enrolled
Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis
Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT07388420·40 enrolled
Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis
Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT07308392·108 enrolled
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia
Recruiting·SShanghai JMT-Bio Inc.·Phase 1/2·NCT07140809·48 enrolled
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Active, not recruiting·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 3·NCT06347003·446 enrolled
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
Active, not recruiting·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 3·NCT05681351·885 enrolled
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
Active, not recruiting·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 3·NCT06347016·311 enrolled
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
Active, not recruiting·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 3·NCT06347133·1,456 enrolled
A Study of SHR-1918 In Participants With Hypertriglyceridemia
Not yet recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 3·NCT07349615·360 enrolled
A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque
Enrolling by invitation·—·N/A·NCT07050134·40 enrolled
Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia
Completed·KKuhnil Pharmaceutical Co., Ltd.·Phase 4·NCT02305355·68 enrolled
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
Completed·Novartis logoNovartis·Phase 2·NCT01594983·58 enrolled
Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
Completed·GGrace Therapeutics Inc.·Phase 2·NCT01516151·289 enrolled
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
Completed·MMochida Pharmaceutical Company, Ltd.·Phase 3·NCT03693131·580 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)